Identification and characterization of *Vibrio vulnificus* plpA encoding a phospholipase A	extsubscript{2} essential for pathogenesis

Received for publication, April 17, 2017, and in revised form, August 28, 2017. Published, Papers in Press, August 30, 2017, DOI 10.1074/jbc.M117.791657

Kyung Ku Jang	extsuperscript{1*}, Zee-Won Lee	extsuperscript{3†}, Bityeoul Kim	extsuperscript{4††}, Young Hyun Jung	extsuperscript{5†}, Ho Jae Han	extsuperscript{5†}, Myung Hee Kim	extsuperscript{6†}, Byoung Sik Kim	extsuperscript{1†}, and Sang Ho Choi	extsuperscript{1†,2†}

From the 	extsuperscript{1}National Research Laboratory of Molecular Microbiology and Toxicology, Department of Agricultural Biotechnology, Center for Food Safety and Toxicology, and the 	extsuperscript{2}Research Institute for Veterinary Medicine, BK21 PLUS Creative Veterinary Research Center, Seoul National University, Seoul 08826, South Korea and the 	extsuperscript{3}Infection and Immunity Research Laboratory, Metabolic Regulation Research Center, Korea Research Institute of Bioscience and Biotechnology, Daejeon 34141, South Korea

Edited by Chris Whitfield

The marine bacterium *Vibrio vulnificus* causes food-borne diseases, which may lead to life-threatening sepsis in some individuals. Therefore, identifying virulence factors in *V. vulnificus* is of high priority. We performed a transcriptome analysis on *V. vulnificus* after infection of human intestinal HT29-methotrexate cells and found induction of plpA, encoding a putative phospholipase, *Vv*PlpA. Bioinformatics, biochemical, and genetic analyses demonstrated that *Vv*PlpA is a phospholipase A	extsubscript{2} secreted in a type II secretion system-dependent manner. Compared with the wild type, the *plpA* mutant exhibited reduced mortality, systemic infection, and inflammation in mice as well as low cytotoxicity toward the human epithelial INT-407 cells. Moreover, *plpA* mutation attenuated the release of actin and cytosolic cyclophilin A from INT-407 cells, indicating that *Vv*PlpA is a virulence factor essential for causing lysis and necrotic death of the epithelial cells. *plpA* transcription was growth phase–dependent, reaching maximum levels during the early stationary phase. Also, transcription factor HlyU and cAMP receptor protein (CRP) mediate additive activation and host-dependent induction of *plpA*. Molecular biological analyses revealed that *plpA* expression is controlled via the promoter, P_{plpA}, and that HlyU and CRP directly bind to P_{plpA} upstream sequences. Taken together, this study demonstrated that *Vv*PlpA is a type II secretion system-dependent secretory phospholipase A	extsubscript{2} regulated by HlyU and CRP and is essential for the pathogenicity of *V. vulnificus*.

The pathogenic marine bacterium *Vibrio vulnificus* is a causative agent of food-borne diseases such as gastroenteritis in healthy people and life-threatening sepsis in individuals with underlying predisposed conditions (for recent reviews, see Refs. 1 and 2). *V. vulnificus* infections are notable for their invasiveness, severe tissue destruction, and rapidly fulminating course of disease, leading to high mortality rates (>50%) and immediate death (within 1–2 days after the first symptoms appear). These pathological features of the disease indicate that the pathogenicity of *V. vulnificus* is a multifactorial and complex phenomenon that involves numerous virulence factors (3). The characterization of somatic and secreted products of *V. vulnificus* has yielded a large list of putative virulence factors, including a carbohydrate capsule, iron-sequestering systems, a cytolsin/hemolysin, an elastolytic metalloprotease, a multifunctional-autoprocessing repeat-in-toxin (MARTX)	extsuperscript{3} toxin, a lipopolysaccharide, a lipase, pili, and flagella to account for the destructive nature of *V. vulnificus* infections (1, 3). Of these putative virulence factors, however, only a few, such as cytolsin/hemolysin and MARTX toxin, have been confirmed as virulence factors that contribute to the lysis and necrotic death of the host cells by using the molecular version of Koch’s postulates (4–6). Therefore, extensive screening and characterization of more virulence factors are still required for understanding the molecular pathogenesis of the multifaceted host–pathogen interaction of *V. vulnificus*.

Phospholipases, lipolytic enzymes hydrolyzing one or more ester linkages in phospholipids, are found in diverse bacterial pathogens, implying that these enzymes play essential roles in the pathogenesis of bacteria (7). Phospholipases are classified into four major groups (A–D) based on their site of action on the phospholipid (7). Among them, phospholipase A (PLA) is able to hydrolyze a fatty acid from the glycero1 backbone and is subdivided into PLA	extsubscript{1} and PLA	extsubscript{2}, each hydrolyzing the fatty acid from the sn-1 and -2 position of the glycerol moiety, respectively (7). Accordingly, PLAs are considered to be bacterial vir-

---

The abbreviations used are: MARTX, multifunctional-autoprocessing repeat-in-toxin; PLA, phospholipase A; MTX, methotrexate; CRP, cAMP receptor protein; *Vv*PlpA, *V. vulnificus* PlpA; qPCR, quantitative PCR; T2SS, type II secretion system; *Vv*PlpA, *V. anguillarum* PlpA; PC, phosphatidyicholine; rPlpA, recombinant *Vv*PlpA protein; MPXI, myeloperoxidase index; ALB, albumin; AST, aspartate aminotransferase; ALT, alanine aminotransferase; LDH, lactate dehydrogenase; MOI, multiplicity of infection; WGA, wheat germ agglutinin; CyPA, cyclophilin A; MEM, minimal essential medium; RLU, relative light unit.

---

1 To whom correspondence may be addressed. Tel.: 82-42-879-8212; E-mail: bskim@kribb.re.kr.
2 To whom correspondence may be addressed. Tel.: 82-2-880-4857; E-mail: choish@snu.ac.kr.

This work was supported by National Research Foundation Mid-career Researcher Program Grant 2015R1A2A1A13001654 from the Ministry of Science, ICT, and Future Planning and the R&D Convergence Center Support Program of the Ministry of Agriculture, Food, and Rural Affairs, Republic of Korea (to S. H. C.). The authors declare that they have no conflicts of interest with the contents of this article.

This article contains supplemental Tables S1 and S2.

† Deceased November 2, 2015.

§ To whom correspondence may be addressed. Tel.: 82-42-879-8212; E-mail: bskim@kribb.re.kr.

*J. Biol. Chem.* (2017) 292(41) 17129 – 17143

© 2017 by The American Society for Biochemistry and Molecular Biology, Inc. Published in the U.S.A.
Characterization of plpA in V. vulnificus

ulence factors disrupting the phospholipid membrane, thus leading to the lysis of human epithelial cells (7). In addition, the products generated by epithelial cell lysis, such as lysophosphatidylcholine, may further act as secondary messengers that induce apoptotic death of human endothelial cells (8). Nevertheless, very little is known about the regulatory mechanisms used by the bacteria to modulate the expression of PLAs (9).

To the best of our knowledge, no definitive analysis of the role of the PLAs in the pathogenesis of V. vulnificus has been reported until now. Furthermore, no genes encoding the PLAs have been identified from V. vulnificus, and thus the molecular mechanisms by which the bacterium modulates the expression of the genes have not yet been characterized. In the present study, we conducted a transcriptome analysis and identified the plpA gene, which is preferentially expressed in V. vulnificus cells exposed to human intestinal HT29-methotrexate (MTX) cells (10, 11). The characteristics of V. vulnificus PlpA (VvPlpA), the product of plpA, were verified experimentally. Construction of the plpA mutant and evaluation of its phenotypes provided strong evidence that VvPlpA contributes to the pathogenesis of V. vulnificus. To elucidate the regulation of the plpA expression, we compared the plpA transcript levels in the wild type and in the mutants lacking various transcription factors. Moreover, the transcriptional unit and promoter of plpA were determined, and the roles of HlyU, a transcription factor regulating virulence genes in Vibrio species (12–14), and cAMP receptor protein (CRP) (15) were analyzed at the molecular level.

Results

Identification and sequence analysis of VvPlpA

The transcriptomes of the V. vulnificus MO6-24/O harvested after either the infection of human intestinal HT29-MTX cells or grown with basal medium Eagle (Gibco-BRL) alone were compared as described under "Experimental procedures." Transcriptome analysis revealed 650 differentially expressed genes in the host cell-exposed V. vulnificus compared with the unexposed one; 319 genes were up-regulated, and 331 were down-regulated (supplemental Tables S1 and S2). Among the up-regulated, virulence-related genes, a gene VVMO6_03257 encoding a putative phospholipase showed the highest-fold change of expression level (20.5-fold, \( p = 0.0001 \)). In contrast, the expressions of several other putative phospholipase genes (VVMO6_00112, 00550, 00661, 01752, 03024, 03759, and 04072) were not significantly induced (data not shown), suggesting that the VVMO6_03257 gene product plays an important role in host–microbe interaction, at least under our experimental conditions. Real-time quantitative PCR (qPCR) confirmed that the expression of VVMO6_03257 is increased about 17.8-fold (\( p = 0.0005 \)) after exposure of V. vulnificus to the host cells (data not shown).

The amino acid sequence deduced from the VVMO6_03257 nucleotide sequence predicted a protein with an N-terminal signal peptide for the type II secretion system (T2SS) (Fig. 1A) (16). The mature protein is composed of 398 amino acids with a theoretical mass of 45.22 kDa and pl of 5.38. When aligned using the Clustal Omega program (http://www.ebi.ac.uk/Tools/msa/clustalo)\(^4\) (66), the deduced amino acid sequence of the mature protein was 69% identical to that of the Vibrio anguillarum phospholipase (VaPlpA) (17), leading us to name the protein VvPlpA. Amino acid sequence analysis further revealed that VvPlpA possesses five conserved blocks for the SGNH hydrolases as well as a GDSL motif found in typical lipases (Fig. 1A) (18). Also, the predicted profile of the hydrophobicity was significantly similar to that of VaPlpA, indicating that VvPlpA is a soluble protein like VaPlpA (data not shown) (17). Meanwhile, we found that the genetic environment of plpA in V. vulnificus is distinct from that in V. anguillarum. Unlike the V. anguillarum plpA located upstream of and sharing the promoter region with hemolysin gene, vah1 (19), V. vulnificus plpA has its own promoter region, and presents at a different location from hemolysin gene, vhA, or MARTX toxin gene, rtxA1 (data not shown).

The secretion of VvPlpA to the cell exterior through T2SS as predicted above was experimentally verified (Fig. 1B). To accomplish this, an isogenic mutant in which the pilD gene encoding the PilD component of T2SS was specifically deleted (20) was used, and the VvPlpA secretion from the mutant was compared with that from the parental wild type. As shown in Fig. 1B, VvPlpA was not detected from the culture supernatant of the pilD mutant. This lack of VvPlpA secretion was restored by the introduction of pMS0908 (20), carrying a pilD gene, to the pilD mutant. These results confirmed that VvPlpA is indeed an extracellular protein, and its secretion is T2SS-dependent.

The lipase activity of VvPlpA, predicted from amino acid sequence analysis, was also experimentally verified. Fluorescence was emitted from the red/green BODIPY PC-A2 (Invitrogen), a fluorescently labeled phosphatidylcholine (PC), in the presence of 0.02–0.5 \( \mu \)g of recombinant VvPlpA protein (rPlpA). The fluorescence emission intensity increased as greater amounts of rPlpA were added (Fig. 1C), suggesting that rPlpA contains the PLA\(_2\) activity cleaving specifically the sn-2 bond of the red/green BODIPY PC-A2 substrate (Invitrogen). Based on the standard curve developed using the honey bee venom PLA\(_2\) (21), the specific activity of rPlpA was calculated to be ~247 units/mg (data not shown) (1 unit = the amount of protein that cleaves 1 \( \mu \)mol of red/green BODIPY PC-A2 per min).

We further examined whether VvPlpA indeed confers the PLA\(_2\) activity to V. vulnificus. For this, an isogenic mutant KK131 lacking a functional plpA gene was constructed (Table 1). When culture supernatant of the wild type, plpA mutant, or complemented strain was added to the reaction as a source for the enzyme, significantly lower fluorescence was emitted from the sample containing that of the plpA mutant compared with the other two samples (Fig. 1D). Therefore, the combined results indicated that VvPlpA is a T2SS-dependent secretory enzyme conferring the PLA\(_2\) activity to V. vulnificus.

VvPlpA is essential for virulence

Next we confirmed the induction of plpA expression under conditions closer to those in vivo rather than those under in

\(^4\) Please note that the JBC is not responsible for the long-term archiving and maintenance of this site or any other third party hosted site.
vitro-cultured host cells. When *V. vulnificus* was inoculated into the blood of uninfected mice, the expression of *plpA* was dramatically elevated (Fig. 2A). This result suggested that *Vv* PlpA may be highly expressed in vivo and take part in the pathogenesis of *V. vulnificus*. To test this hypothesis, the virulence of wild type and *plpA* mutant KK131 was compared in mice. As shown in Fig. 2B, mice intragastrically infected with the wild type started to die at 5 h postinfection. In contrast, the survival time of mice infected with KK131 was consistently and significantly prolonged (*p* < 0.005, log-rank test). At 20 h postinfection, the percentages of surviving mice were 28 and 57% for the wild type– and KK131–infected group, respectively (Fig. 2B).

To further elucidate the role of *Vv* PlpA during pathogenesis, we compared the number of *V. vulnificus* in the blood and various hematological indexes of either the wild type– or *plpA* mutant–infected mice. To deliver exactly the same number of *V. vulnificus* into the host without any colonization problems, we adopted an intraperitoneal infection model for these analyses. First, we confirmed the importance of *Vv* PlpA in this infection model by comparing the survival rates of mice infected with the wild type or *plpA* mutant (data not shown). When the bacteria in the blood of the infected mice were enumerated, about 4 times more wild-type cells, compared with the *plpA* mutant cells, were recovered (Fig. 2C). Consistent with this, hematological analyses revealed that the levels of myeloperoxidase index (MPXI) and albumin (ALB), the biomarkers for sepsisemia (in inverse correlation; see Refs. 22 and 23), were significantly lower in the wild type–infected mice compared with those in the *plpA* mutant–infected or PBS-treated mice (Fig. 2, D and E). Also, mice infected with the wild type exhibited significantly higher levels of aspartate aminotransferase (AST) and alanine aminotransferase (ALT) activities, the indexes for liver damage (24), compared with those infected with the *plpA* mutant or treated with PBS (Fig. 2F). Combined with the fact that *plpA* mutation does not attenuate the bacterial fitness in vitro (data not shown), these results clearly demonstrated the crucial role of *Vv* PlpA in *V. vulnificus* systemic

---

**Figure 1.** Analysis of amino acid sequence, secretion, and enzymatic activity of *Vv* PlpA. A, the amino acid sequences retrieved from the NCBI protein database (http://www.ncbi.nlm.nih.gov) (accession numbers ADV88279 for *Vv* PlpA and AAY26144 for *Va* PlpA) were aligned using the Clustal Omega and Genedoc program. Identical residues (gray boxes) and missing sequence (dash) are indicated. The putative signal peptides and consensus blocks for SGNH hydrolases are boxed by a black line. The GDSL motif is indicated by asterisks. The four residues conserved in the SGNH hydrolases are indicated by black-filled inverse triangles. B, *Vv* PlpA in the supernatants of the *V. vulnificus* strains grown to an *A*\textsubscript{600} of 0.9 was detected by Western blot analysis. Molecular size markers (Bio-Rad) are shown in kDa. C and D, PLA2 activity was examined by measuring fluorescence intensity emitted from the fluorogenic phosphatidylcholine substrate (red/green BODIPY PC-A2) after incubation with various amounts of the *rPlpA* (C) or supernatants of the *V. vulnificus* strains (D) for 0.5 h. Error bars, S.D. Statistical significance was determined by Student’s t test. *, *p* < 0.05 relative to the wild type. WT pJH0311 and WT pRK415, wild type; *pilD* pJH0311, *pilD* mutant; *plpA* pJH0311 and *plpA* pRK415, *plpA* mutant; *pilID* pMS0908 and *plpA* pKK1320, complemented strains.
infection, and the accompanying inflammation resulted in host death.

**VvPlpA is essential for the lysis and necrotic death of host cells**

To investigate the role of VvPlpA in the cytotoxicity toward host cells, the activities of lactate dehydrogenase (LDH) released from INT-407 cells infected with the wild type and plpA mutant KK131 were determined. As shown in Fig. 3A, KK131 exhibited significantly decreased LDH-releasing activity compared with that of the wild type, when the *V. vulnificus* strains were used to infect the INT-407 cells at multiplicity of infection (MOI) of 1, 5, and 20 for 2 h. Similarly, INT-407 cells infected with KK131 at an MOI of 10 and then incubated for 1, 2, and 3 h released lower levels of LDH compared with those infected with the wild type (Fig. 3B), indicating that VvPlpA plays an important role in *V. vulnificus* infecting and injuring host cells (Fig. 3, A and B). Complementation of the *plpA* mutation with a functional *plpA* gene (pKK1320) restored the LDH-releasing activity of KK131 to levels comparable with those of the wild type (Fig. 3, A and B). Therefore, the decreased cytotoxicity of KK131 resulted from the inactivation of *plpA* rather than the reduced expression of other genes downstream of *plpA*.

To further understand the effects of VvPlpA on host cells, INT-407 cells were stained with Texas Red®-X–conjugated wheat germ agglutinin (WGA) (Thermo Fisher Scientific, San Jose, CA) and Hoechst® 33342 (Thermo Fisher Scientific), after which their morphological changes caused by infection with the *V. vulnificus* strains were examined. As shown in Fig. 3C, INT-407 cells exhibited typical morphology of surface-attached epithelial cells with regularly shaped cell margins and rounded nuclei in the absence of infection (PBS). Infection with the wild type injured INT-407 cells and resulted in severely shrunken cell morphology with irregular cell margins, presumably accompanied by the release of cellular materials (WT (pRK415)). Notably, however, infection with the *plpA* mutant KK131 resulted in cells with less severely shrunken and swollen host death.

### Table 1

| Plasmids and bacterial strains used in this study |
|-----------------------------------------------|
| **Strain or plasmid** | **Relevant characteristics** | **Reference or source** |
| V. vulnificus | | |
| MO6-24/O | Wild type; clinical isolate; virulent | Ref. 65 |
| KK131 | MO6-24/O with ΔplpA | This study |
| ZW141 | MO6-24/O with ΔpilI | This study |
| DI0201 | MO6-24/O with ΔcypA | This study |
| KK151 | MO6-24/O with ΔpilIΔcypA | This study |
| MS023 | MO6-24/O with ΔplpA | Ref. 20 |
| E. coli | | |
| S17-1pir | λ-pir lysogen; thi pro hadR hadD* recA RP4–2 Tc: Mu-Km: Tn7; Tp' Sm'; host for T-requiring plasmids: conjugal donor | Ref. 55 |
| BL121 (DE3) | F– ompT hadD (rpsL mcrA) gal dcm (DE3) | Laboratory collection |

---

* plpA, prolyl isomerase; Smr, streptomycin-resistant; Cmr, chloramphenicol-resistant; Tcr, tetracycline-resistant; Apr, ampicillin-resistant; Kmr, kanamycin-resistant.
Characterization of \textit{plpA} in \textit{V. vulnificus}

To identify transcription factor(s) associated with the \textit{plpA} regulation, levels of \textit{plpA} mRNA were compared in the wild type and several mutants lacking a transcription factor known to regulate the virulence of \textit{V. vulnificus}. The transcription factor-lacking mutants consisted of \textit{fur}, \textit{hlyU}, \textit{iscR}, \textit{aphB}, \textit{crp}, \textit{leuO}, and \textit{smcR} mutants (13, 26–30). Expression of \textit{plpA} did not differ in the wild type or mutants lacking \textit{Fur}, \textit{IscR}, \textit{AphB}, \textit{LeuO}, or a quorum-sensing master regulator \textit{SmcR} (27) (data not shown). This result suggested that \textit{plpA} might not be regulated by iron availability or by quorum sensing. In contrast, the \textit{hlyU} and \textit{crp} mutants showed almost 2.5-fold lower levels of \textit{plpA} transcript compared with those in the wild type (Fig. 4B), indicating that both \textit{HlyU} and \textit{CRP} may act as positive regulators. The levels of \textit{VvPlpA} determined by Western blot analyses also decreased in the culture supernatants of the \textit{fur}, \textit{hlyU}, and \	extit{crp} mutants (13, 26–30).

Transcription of \textit{plpA} is growth phase–dependent and regulated by \textit{HlyU} and \textit{CRP}

To extend our understanding of \textit{plpA} regulation, levels of \textit{plpA} transcript in the wild type grown under various conditions (oxidative stress, iron limitation, and different temperatures) were compared, but none of the tested conditions influenced \textit{plpA} expression (data not shown). However, when the levels of \textit{plpA} mRNA were analyzed at various growth phases, the \textit{plpA} transcript level increased to maximum levels in the early stationary phase (A$_{600} = 1.0$) and then decreased in the late stationary phase (A$_{600} = 2.5$) (Fig. 4A), indicating growth phase–dependent expression of \textit{plpA}.

To identify transcription factor(s) associated with the \textit{plpA} regulation, the levels of \textit{plpA} mRNA were compared in the wild type and \textit{VvPlpA} mediating host cell lysis as well as necrotic death by releasing cytosolic components. Therefore, these results, combined with the previous results of decreased mouse mortality and LDH-releasing activity in the absence of \textit{VvPlpA}, indicated that \textit{VvPlpA} is a virulence factor essential for cell lysis and necrotic cell death, thereby contributing to the pathogenesis of \textit{V. vulnificus}.

\textbf{Figure 2.} \textit{VvPlpA} is essential for pathogenesis of \textit{V. vulnificus}. \textit{A}, the wild type grown to an A$_{600}$ of 0.5 was exposed to either LBS or blood of uninfected mice (n = 3) for 1 or 2 h and then used to isolate total RNAs. The \textit{plpA} mRNA was determined by real-time qPCR analyses, and the \textit{plpA} mRNA level in the bacteria exposed to LBS was set as 1. B, 7-week-old female ICR mice (n = 13 group), injected intraperitoneally with iron-dextran, were intragastrically infected with the wild type and \textit{plpA} mutant at doses of 10$^5$ cfu. C–F, the mice, without an iron-dextran administration, were intraperitoneally infected with the wild type (n = 11), \textit{plpA} mutant (n = 11), or PBS (n = 5, control) at doses of 10$^5$ cfu and then sacrificed to obtain blood at 4 h postinfection. C, the number of either the wild type or \textit{plpA} mutant in the blood of infected mice (n = 6 per group) was enumerated as cfu/100 µl of blood. Each open symbol represents an individual mouse. Black-filled inverted triangles indicate median values. D–F, the levels of MPXI (D), ALB (E), and AST/ALT (F) in the wild type– or \textit{plpA} mutant–infected or PBS-treated mice (n = 5 per group) were determined by hematological analyses. Error bars, S.D. Statistical significance was determined by Student’s t test for \textit{A} and \textit{C}–\textit{F}, and by log-rank test for \textit{B}. *p < 0.05; **, p < 0.005; ns, not significant. WT, wild type; \textit{plpA}, \textit{plpA} mutant; PBS, control.
positively regulate \( \textit{plpA} \) expression at the transcriptional level.

**Additive activation of \( \textit{plpA} \) by \( \text{HlyU} \) and \( \text{CRP} \)**

To characterize the functions of \( \text{HlyU} \) and \( \text{CRP} \) in \( \textit{plpA} \) expression, \( \text{hlyU crp} \) double mutant KK151 was constructed and used to determine \( \textit{plpA} \) expression. Lack of both \( \text{hlyU} \) and \( \text{crp} \) in KK151 resulted in a significant reduction of \( \textit{plpA} \) expression, as the transcript level was only one-quarter of that in the wild type (Fig. 5A). Furthermore, this residual \( \textit{plpA} \) transcript level in KK151 was considerably lower than that in either the \( \text{hlyU} \) or \( \text{crp} \) single mutant (Fig. 5A), suggesting that both transcriptional regulators activate \( \textit{plpA} \) additively. Indeed, the cellular level of \( \text{HlyU} \) in the \( \text{crp} \) mutant (or \( \text{CRP} \) in the \( \text{hlyU} \) mutant) was comparable with that in the wild type (Fig. 5B), confirming that neither \( \text{CRP} \) nor \( \text{HlyU} \) controls the expression of the other in a sequential regulatory cascade.

To further determine whether increasing the level of cellular \( \text{HlyU} \) could compensate for the lack of \( \text{CRP} \) in the activation of \( \textit{plpA} \), KK151 was complemented with pZW1510 expressing \( \text{hlyU} \) under the lac promoter. When \( \text{hlyU} \) was induced by isopropyl-\( \beta \)-D-thiogalactopyranoside, the HlyU level in KK151 (pZW1510) was significantly increased, exceeding the level in the wild type or \( \text{crp} \) single mutant (Fig. 5B). Nonetheless, the \( \textit{plpA} \) transcript level in KK151 (pZW1510) was still lower than that in the wild type, corresponding to only about 60% of that in the wild type (Fig. 5A). This result suggested that if \( \text{CRP} \) is absent, overexpressed \( \text{HlyU} \) is insufficient in increasing \( \textit{plpA} \) expression levels comparable with those in the wild type. Similarly, overproduced \( \text{CRP} \) (Fig. 5B) was unable to completely compensate for the lack of \( \text{HlyU} \) in the activation of \( \textit{plpA} \) (Fig. 5A). Also, the changes in the \( \textit{plpA} \) transcript were directly reflected on the secreted \( \text{VvPlpA} \) protein levels (Fig. 5B).

Next, we verified whether \( \text{HlyU} \) and \( \text{CRP} \) are involved in the induction of \( \textit{plpA} \) during exposure to host cells by comparing the \( \textit{plpA} \) transcript levels in the \( \text{V. vulnificus} \) strains exposed to either minimal essential medium (MEM, control) or INT-407 cells for 1 h. As shown in Fig. 5C, the \( \textit{plpA} \) transcript level in the
**Characterization of plpA in V. vulnificus**

**Figure 4. Expression of plpA in V. vulnificus** under different growth phases (A) or with different genetic backgrounds (B and C). A, total RNAs from the V. vulnificus wild type under different growth phases were isolated, and the plpA mRNA levels were determined by real-time qPCR analyses. The plpA mRNA level in the cells grown to an A600 of 0.3 was set as 1. B and C. V. vulnificus strains were grown to an A600 of 0.9 and used to determine the plpA mRNA and VvPlpA levels. The plpA mRNA levels in the total RNAs isolated from the cultures were determined by real-time qPCR analyses, and the plpA mRNA level in the wild type was set as 1. The VvPlpA levels in the supernatants harvested from the cultures were determined by Western blot analyses. Molecular size markers (Bio-Rad) are shown in kDa. Error bars, S.D. Statistical significance was determined by Student's t test. **, p < 0.005 relative to the cells grown to an A600 of 0.3 (for A) or to the wild type (for B and C); ns, not significant. WT pJH0311, wild type; hlyU pJH0311, hlyU mutant; crp pJH0311, crp mutant; hlyU pZW1510 and crp pKK1502, complemented strains.

**Figure 5. HlyU and CRP mediate additive activation and host-dependent induction of plpA.** A and B. V. vulnificus strains were grown to an A600 of 0.9 and used to determine the plpA mRNA levels and VvPlpA, HlyU, CRP, and DnaK protein levels. A, the plpA mRNA levels were determined by real-time qPCR analyses, and the plpA mRNA level in the wild type was set as 1. B, the secreted VvPlpA and cellular HlyU, CRP, and DnaK (as an internal control) levels were determined by Western blot analyses. Molecular size markers (Bio-Rad) are shown in kDa. C. V. vulnificus strains were exposed to MEM (control) or INT-407 cells at an MOI of 10 for 1 h and then used to isolate total RNAs. The plpA mRNA levels were determined by real-time qPCR, and the plpA mRNA level in the wild type exposed to MEM was set as 1. Error bars, S.D. Statistical significance was determined by Student’s t test. *, p < 0.05; **, p < 0.005; ns, not significant. WT and WT pJH0311, wild type; hlyU and hlyU pJH0311, hlyU mutant; crp and crp pJH0311, crp mutant; hlyU crp pJH0311, hlyU crp double mutant; hlyU crp pZW1510 or hlyU crp pKK1502, hlyU crp double mutant overexpressing HlyU or CRP, respectively.

**hlyU or crp mutant** was significantly lower than that in the wild type, regardless of host cell exposure. Importantly, the host-dependent induction of plpA was evident in the wild type (3.36-fold induction; p = 0.0002), but not in either the hlyU or crp mutant (p = 0.67 or 0.054, respectively). Taken together, the results indicated that HlyU and CRP additively activate plpA expression, and thus both regulators are simultaneously required for the full activation of plpA. Furthermore, these regulators are essential for the induction of plpA in V. vulnificus during infection of host cells.

**Determination and deletion analyses of the plpA promoter, P_{plpA}**

To map the promoter of plpA, the transcription start site of plpA was determined by primer extension analysis. A single reverse transcript was produced from the primer extension of the RNA isolated from the wild type grown to an A600 of 0.9
Characterization of plpA in V. vulnificus

To delineate the cis-DNA sequences in \( P_{plpA} \) required for HlyU- and CRP-mediated activation, pKK reporters carrying the \( P_{plpA} \) regulatory region, which was deleted up to different 5’-ends and fused transcriptionally to luxCDABE, were constructed (Fig. 7A). The reporters were transferred into the \( V. \) vulnificus strains, and cellular luminescence was used to quantify the ability of each \( P_{plpA} \) regulatory region to activate the promoter (Fig. 7B). The luminescence produced by pKK1516 carrying \( P_{plpA} \) deleted up to 227 was \( \sim 1.1 \times 10^4 \) relative light units (RLUs) in the wild type but significantly reduced in the hlyU and \( crp \) mutants, supporting our previous observation that HlyU and CRP coactivate plpA expression. Compared with pKK1514, pKK1515 carrying \( P_{plpA} \), deleted up to 157 produced significantly reduced RLUs in the wild type. Moreover, the RLUs of the wild type and the hlyU mutant containing pKK1515 did not significantly differ, indicating that the cis-DNA sequences required for HlyU to activate \( P_{plpA} \) are deleted in pKK1515. Similarly, the comparable levels of RLUs produced by pKK1516 in the wild type and \( crp \) mutant indicated that deletion of the \( P_{plpA} \) regulatory region up to 77 probably impairs CRP (in addition to HlyU) activation of \( P_{plpA} \). The undetectable luminescence in the wild type (and the \( hlyU \) or \( crp \) mutant) containing pKK1517 indicated that deletion of the \( P_{plpA} \) regulatory region up to +22 results in a complete loss of \( P_{plpA} \) activity. These results implied that cis-DNA sequences essential for HlyU and CRP to activate \( P_{plpA} \) encompass the -157 and -77 regions, respectively.

HlyU and CRP regulate by binding directly to \( P_{plpA} \)

To examine whether HlyU and CRP bind directly to the promoter \( P_{plpA} \), EMSAs were performed as shown in Fig. 8 (A and B). For this purpose, the 461-bp labeled DNA probe encompassing the \( P_{plpA} \) regulatory region (from -345 to +116) was incubated with increasing amounts of HlyU or CRP and then subjected to electrophoresis. EMSA revealed that the addition of HlyU to the DNA probe resulted in two retarded bands in a concentration-dependent manner, indicating that HlyU binds directly to at least two binding sites with different affinities (Fig. 8A). Furthermore, this binding of HlyU was specific because the EMSA was performed in the presence of a nonspecific competitor, poly(dI-dC) (0.1 \( \mu \)g; Sigma). In the second EMSA, the same but unlabeled 461-bp DNA probe was used as a self-competitor, which competed for the binding of HlyU in a dose-dependent manner (Fig. 8A), confirming that HlyU binds specifically as well as directly to \( P_{plpA} \). Similarly, EMSAs demonstrated that CRP also binds directly and specifically to the \( P_{plpA} \) regulatory region (Fig. 8B). The combined results suggested that HlyU and CRP regulate plpA by directly binding to their specific regions within \( P_{plpA} \) rather than by modulating the cellular levels of unidentified transacting factor(s), which in turn binds directly to \( P_{plpA} \).

DNase I protection assays were performed using the same 461-bp DNA probe to identify the HlyU-binding sequences in the \( P_{plpA} \) regulatory region (Fig. 8C). When HlyU was used up to 50 nm, the HlyU footprint extended from -191 to -157 (HLYUB1, centered at -174) (Fig. 8C). Upon increasing HlyU levels, two additional sequences extending from -151 to -128 (HLYUB2, centered at -139.5) and -126 to -93 (HLYUB3, centered at -109.5) were protected from DNase I digestion (Fig. 8C). Inspection of the HLYUBs revealed AT-rich sequences with an (imperfect) inverted repeat (Fig. 6B), indicating that HlyU binds to the sequences in the form of a dimer, as proposed previously (13, 31). Similarly, DNase I protection assays revealed the sequences of the region protected by CRP binding (Fig. 8D). The sequences of the protected region extended from -82 to -57 (CRPB, centered at -69.5) and scored 81% similarity to a consensus sequence for the binding of CRP (the TGTGA\(^6\)-TCACA; see Ref. 32) (Fig. 6B). The positioning of HLYUBs and CRPB suggested that both HlyU and CRP may act as class I activators interacting with the C-terminal domain of RNA polymerase \( \alpha \) subunits (33). Taken together, these results demonstrated that HlyU and CRP regulate plpA directly by binding to the specific sequences of \( P_{plpA} \).
Discussion

The epithelial surface of the gastrointestinal tracts is the major site of entry for *V. vulnificus*, an enteropathogen, to invade the host. Several methods, such as *in vivo*-induced antigen technology and *in vivo* expression technology, have been developed and adopted to discover *V. vulnificus* genes expressed preferentially in the host (34, 35). Although previous transcriptome analyses identified *V. vulnificus* genes induced specifically during infection, functional and regulatory features of the induced genes have been barely characterized (36, 37). In this study, *plpA* encoding a PLA₂ of *V. vulnificus*, VvPlpA, was identified among the transcriptome profile expressed preferentially during infection of human intestine HT29-MTX cells (supplemental Tables S1 and S2) and then further characterized at molecular levels. As a part of the results, the ability of VvPlpA to cleave the sn-2 bond in the fluorescently labeled PC was demonstrated (Fig. 1C). Consistent with this, rPlpA showed hemolytic activity on human and horse erythrocyte containing about 29 and 38% PC in its membrane (38, 39), respectively, but not to PC-deficient sheep erythrocyte (38).
(data not shown). These results suggested that PC is a preferential substrate for \( VvPlpA \), as is the case for \( VaPlpA \) (17). Moreover, compared with the wild type, the \( plpA \) mutant, KK131, showed significantly attenuated virulence; it showed reduced systemic infection, liver damage, and mortality in mice (Fig. 2, B–F). These results led us to conclude that \( VvPlpA \), which is secreted in a T2SS-dependent manner, is an essential virulence factor contributing to \( V.\ vulnificus \) pathogenesis along with other toxins, such as cytolysin/hemolysin and MARTX toxin (5, 40, 41). Indeed, the expression of neither the cytolysin/hemolysin gene, \( vvhA \), nor the MARTX toxin gene, \( rtxA1 \), was affected by \( plpA \) mutation in \( V.\ vulnificus \) (data not shown). Furthermore, we found that the genes encoding \( VvPlpA \) homologues are highly conserved and expressed well in various clinical and environmental isolates of \( V.\ vulnificus \) (data not shown), further supporting its crucial role in the adaptation of \( V.\ vulnificus \) to variety of environments, including the host interior. One such role of \( VvPlpA \) during infection is that this lipolytic enzyme disrupts membranes of intestine epithelial cells and thereby allows the pathogen to invade other tissues (or organs), such as blood vessels, where the pathogen most likely secretes additional toxins.

It has been reported that many pathogenic bacteria, including \( Salmonella \) spp. and \( Yersinia\ enterocolitica \), induce necrotic death of the host epithelial barrier and immune cells to survive and spread easily in the host (42, 43). Consistent with this, \( V.\ vulnificus \) infection also manifests robust necrotic cell death and tissue destruction, which are caused by toxins such as MARTX, resulting in skin lesions (6, 44, 45). This study found that \( VvPlpA \), in addition to the MARTX toxin, also contributes to the induction of necrotic death of INT-407 epithelial cells (Fig. 3D). Therefore, the combined results suggested that \( VvPlpA \) is essential for the necrotic death of human epithelial cells (Fig. 3).

Many pathogenic bacteria continually encounter environmental changes and cope with harsh conditions in the host. Therefore, the ability to constantly sense and respond to the host environment is important for the pathogens to establish successful infection (46, 47). Accordingly, pathogens have evolved sophisticated mechanisms to extensively regulate their gene expressions, which consequently plays a key role in the adaptation and pathogenesis of the bacteria to the host (46, 47). This study revealed that \( V.\ vulnificus \) regulates the expression of \( plpA \) in a growth phase–dependent manner and to the maximum level in the early stationary phase (Fig. 4A). Because this growth-phase dependent \( plpA \) expression was further confirmed by using a \( P_{\ plpA} \)-\( luxCDABE \) transcriptional fusion reporter (data not shown), it seems that the regulation of \( plpA \) expression occurred at a transcriptional level rather than a post-transcriptional level. Consistent with this, HlyU and CRP were found to directly activate \( plpA \) transcription both in vitro and ex vivo (Figs. 5 and 8). Because the expression of HlyU is induced specifically during the infection (34), the positive control of \( VvPlpA \) by HlyU could enable \( V.\ vulnificus \) to express this critical virulence factor at the right place (i.e. inside the host). In addition, CRP, which is a central regulator of energy (catabolic) metabolism (15) may recognize host environments by sensing the starvation of specific nutrients imposed by the host cells and endogenous bacterial flora (47). Accordingly, CRP might contribute to the production of \( VvPlpA \) at the appropriate time when \( V.\ vulnificus \) encounters such nutrient starvation, probably leading to immune deficiency in the host. Taken together, \( V.\ vulnificus \) could express \( plpA \) in a spatially and temporally regulated fashion to obtain maximum effectiveness during pathogenesis.

Although a few examples of transcriptional coactivation of bacterial virulence genes by multiple activators have been reported (11, 48), coactivation by HlyU and CRP has not yet been reported. Each HlyU and CRP binds to the upstream sequence of \( P_{\ plpA} \) and activates the promoter as a solitary regulator, albeit not to levels comparable with that of the wild type (Figs. 5 and 8). Overproduced HlyU (or CRP) failed to fully compensate for a lack of CRP (or HlyU), indicating that both HlyU and CRP are required for the expression of \( VvPlpA \) to the wild-type level (Fig. 5, A and B). Obviously, this coactivation of \( P_{\ plpA} \) by both HlyU and CRP, which probably sense and incorporate different signals from the environment, as mentioned above, could allow the tight regulation and fine tuning of \( VvPlpA \) expression during pathogenesis. It is also noteworthy that HlyU and/or CRP are involved in the activation of the expression of other virulence factors, such as the MARTX toxin, cytolysin/hemolysin, \( VvPpE \) (an elastolytic protease), \( GbpA \) (a mucin-binding protein), and \( HupA \) (a heme receptor protein), in addition to \( VvPlpA \) (11, 13, 48–50). It is likely that regulation by common regulatory proteins provides precisely coordinated expression of multiple virulence factors, thereby facilitating the cooperation of the virulence factors crucial for the overall success of the organism during pathogenesis.

In summary, a transcriptome analysis identified \( V.\ vulnificus \) \( plpA \) among the genes, which are specifically induced when the pathogen is exposed to human intestine HT29-MTX cells. \( VvPlpA \) is a T2SS-dependent secretory \( PLA_2 \) and promotes lysis and necrotic death of host cells, thereby contributing to the pathogenesis of \( V.\ vulnificus \), as determined in the mouse infection model. The expression of \( plpA \), which reaches maximum levels at the early stationary growth phase, is activated by the global regulators HlyU and CRP at the transcriptional level. HlyU and CRP mediate the host-dependent induction of \( plpA \) and exert their effects by directly binding to the regulatory region of \( P_{\ plpA} \). The collaborative regulation of \( plpA \) by the global regulators could facilitate cooperation of \( VvPlpA \) with other virulence factors to obtain maximum effectiveness, thereby enhancing the overall success of \( V.\ vulnificus \) during infection.

Experimental procedures

**Strains, plasmids, and culture conditions**

The strains and plasmids used in this study are listed in Table 1. Unless otherwise noted, the \( V.\ vulnificus \) strains were grown aerobically in LB medium supplemented with 2% (w/v) NaCl (LBS) at 30 °C, and their growth was monitored spectrophotometrically at 600 nm (\( A_{600} \)).

**Transcriptome analyses**

\( V.\ vulnificus \) MO6-24/O (wild type) cells were used either to infect HT29-MTX intestinal epithelial cells at an MOI of 10 or
Table 2
Oligonucleotides used in this study

| Name                             | Oligonucleotide sequence (5′ → 3′)abc | Use                      |
|----------------------------------|--------------------------------------|--------------------------|
| **For mutant construction**      |                                       |                          |
| PLPA01-F                         | ATGAAGAAGATGACTATTCTCTTTGTTGTCG       | Deletion of plpA ORF     |
| PLPA01-R                         | GTGAGTTTCTCACTCATTACGCAGTCAAGC       | Deletion of plpA ORF     |
| PLPA02-F                         | GGGATTTCCTCTTCTTCTTCTTCCTTCTGATG     | Deletion of plpA ORF     |
| PLPA02-R                         | TGAAGCTGTTGAGTTGGCCCACTTG            | Deletion of hlyU ORF     |
| HLYU01-F                         | CTGCTTGTGAGTTGGCCCACTTG             | Deletion of hlyU ORF     |
| HLYU01-R                         | GAGCTCTTGGCTATGCAATATGC              | Deletion of hlyU ORF     |
| HLYU02-F                         | AAGATTTCTCTTCACTCTTCTTCTTCTTCTG     | Deletion of hlyU ORF     |
| HLYU02-R                         | GACGACAAAACTTCGCCGGCC               | Deletion of hlyU ORF     |
| **For mutant complementation**   |                                       |                          |
| PLPA03-F                         | GMCTGCAATAGTTACAGGTTACGTG           | Amplification of plpA ORF |
| PLPA03-R                         | GAGCTCTTAACTTCACTACTCACTACTG        | Amplification of plpA ORF |
| HLYU03-F                         | GAGCTCTTCACTACTCACTACTCACTG         | Amplification of plpA ORF |
| HLYU03-R                         | GACGACAAAACTTCGCCGGCC               | Amplification of plpA ORF |
| CRP01-F                          | GACGCTCACTCTTCTGCTGTC               | Amplification of ORF     |
| CRP01-R                          | GACGACAAAACTTCGCCGGCC               | Amplification of ORF     |
| **For protein overexpression**   |                                       |                          |
| PLPA04-F                         | CATATGAGCTCCCTTCTTCTTCTTCTGAG       | Amplification of plpA-his, ORF |
| PLPA04-R                         | ACTATGCTCTTCTTCTTCTTCTTCTTCTGAG     | Amplification of truncated plpA ORF |
| PLPA05-F                         | CGGATCCGAGCTCCCTTCTTCTTCTTCTGAG     | Amplification of truncated plpA ORF |
| PLPA05-R                         | CTGCAAGCTCCCTTCTTCTTCTTCTTCTGAG     | Amplification of truncated plpA ORF |
| HLYU04-F                         | CCTGCAAGCTCCCTTCTTCTTCTTCTGAG       | Amplification of truncated plpA ORF |
| HLYU04-R                         | CCTGCAAGCTCCCTTCTTCTTCTTCTGAG       | Amplification of truncated plpA ORF |
| **For real-time qPCR**           |                                       |                          |
| PLPA-qRT-F                       | TTTGCTGTTGACAGGCCAAAAATGGCC         | Quantification of the16s RNA expression |
| PLPA-qRT-R                       | CGACGCTACCAAAATGGCCAAATGGCC         | Quantification of the16s RNA expression |
| 16S-qRT-F                        | CGACGCTACCAAAATGGCCAAATGGCC         | Quantification of the16s RNA expression |
| 16S-qRT-R                        | CGACGCTACCAAAATGGCCAAATGGCC         | Quantification of the16s RNA expression |
| **For primer extension analysis, EMSA, and DNase I protection assay** | | |
| PLPA06-F                         | GCTTAAATGACCACTGTTAGAAA             | Amplification of plpA upstream region |
| PLPA06-R                         | CTGCAAGATGAGCTGCACAAAA             | Amplification of plpA upstream region |
| **For promoter deletion analysis** |                                       |                          |
| PLPA001                          | GCTGCTCTTAAAGATGACCGGGAAACGAATCGG   | Deletion of plpA regulatory region |
| PLPA002                          | GCTGCTCTTAAAGATGACCGGGAAACGAATCGG   | Deletion of plpA regulatory region |
| PLPA003                          | GCTGCTCTTAAAGATGACCGGGAAACGAATCGG   | Deletion of plpA regulatory region |
| PLPA004                          | GCTGCTCTTAAAGATGACCGGGAAACGAATCGG   | Deletion of plpA regulatory region |
| PLPA005                          | GCTGCTCTTAAAGATGACCGGGAAACGAATCGG   | Deletion of plpA regulatory region |

a The oligonucleotides were designed using the V. vulnificus MO6-24/O genomic sequence (GenBank™ accession number CP002469 and CP002470; www.ncbi.nlm.nih.gov).
b Regions of oligonucleotides not complementary to the corresponding genes are underlined.

to grow in the basal medium Eagle (Gibco-BRL) alone (as a negative control) for 2 h and were then harvested. Total RNAs were isolated from the bacteria using RNAprotect® bacteria reagent and the miRNeasy® minikit (Qiaegen, Valencia, CA), fragmented, and used to synthesize double-stranded cDNA, as described previously (TruSeq® Stranded mRNA Sample Prep Kit, Illumina, San Diego, CA) (51). The cDNA library was amplified by PCR, sequenced, and then counted as the numbers of reads per kilobase of transcript per million mapped reads to normalize the expression levels of specific genes as described previously (52). These values, normalized using the quintile normalization procedure, were statistically analyzed by t tests to identify the genes expressed differentially (>4-fold change with p ≤ 0.05) when exposed to the HT-29 MTX cells.

**Generation and complementation of the plpA, hlyU, and hlyU crp mutants**

The plpA gene was inactivated in vitro by deletion of the ORF of plpA (353 of 1254 bp) using the PCR-mediated linker-scanning mutation method as described previously (53). Briefly, pairs of primers PLPA01-F and -R (for amplification of the 5′-ORF) or PLPA02-F and -R (for amplification of the 3′-ORF) were designed and used (Table 2). The resulting ΔplpA was amplified by PCR using the mixture of both amplicons as the template and PLPA01-F and PLPA02-R as primers. Similar experimental procedures were adopted for amplification of the ΔhlyU in vitro, except that primers HLYU01-F, HLYU01-R, HLYU02-F, and HLYU02-R (for 249-bp deleted hlyU) were used as indicated in Table 2. The resulting ΔplpA and ΔhlyU were ligated into SpeI-SphI–digested pDM4 (54) to generate pKK1301 and pZW1401, respectively (Table 1). E. coli S17-1 λpir, tra strain (55) containing pKK1301 or pZW1401 was used as a conjugal donor to V. vulnificus MO6-24/O to generate either the plpA mutant KK131 or the hlyU mutant ZW141, respectively (Table 1). Similarly, E. coli S17-1 λpir, tra containing pBS0907, which was constructed previously to carry hlyU, was used as a conjugal donor to ZW141 to generate the hlyU crp double mutant KK151 (Table 1). The conjugation and isolation of the transconjugants were conducted using the method described previously (56).

To complement the plpA, hlyU, crp, and pilD (constructed previously (20)) mutations, each ORF of plpA, hlyU, crp, and pilD was amplified by PCR using a pair of specific primers, as listed in Table 2. The amplified plpA, hlyU, crp, and pilD ORFs were cloned into the broad-host-range vector pRK415 (for
Characterization of plpA in V. vulnificus

plpA (57) and pJH0311 (for hlyU, crp, and pilD) (58) under the lac promoter to create pKK1320, pZW1510, pKK1502, and pMS50908, respectively (Table 1). The plasmids were transferred into the appropriate mutants by conjugation as described above. For complementation tests, when the cultures reached an A600 of 0.3, isopropyl-β-D-thiogalactopyranoside was added to a final concentration of 0.1 mM to induce the expression of the recombinant genes on the plasmids.

Protein purification and Western blot analysis

The ORF of plpA with a His6 tag was amplified by PCR using a pair of primers, PLPA04-F and -R (Table 2), digested with Ncol and Sall, and ligated into pMBP parallel 1 (59), resulting in pKK1503 (Table 1). The maltose-binding protein-PlpA-His6 protein was expressed in E. coli BL21 (DE3), the maltose-binding protein portion was removed, and the His6-tagged rPlpA was further purified using a HiLoad Superdex 200 gel filtration column according to the manufacturer’s procedures (GE Healthcare). The purified rPlpA was used to perform a PLA2 activity assay. To raise a polyclonal antibody against PlpA, an N-terminal region of PlpA (amino acids 1–150) was subcloned into pET-28a(+) (Novagen, Madison, WI) using primers PLPA05-F and -R (Table 2), resulting in pKK1504 (Table 1). The ORF of hlyU was subcloned into pET-28a(+) using a pair of primers HLYU04-F and -R (Table 2), resulting in pYU1317 (Table 1). The plasmid pHK0201 containing an ORF for His-tagged CRP was previously constructed (Table 1) (49). The His-tagged truncated PlpA, HlyU, and CRP were expressed in E. coli BL21 (DE3) and purified by affinity chromatography (Qiagen).

The purified His6-tagged truncated PlpA, HlyU, and CRP proteins were used to raise rabbit polyclonal antibodies to PlpA, HlyU, and CRP of V. vulnificus, respectively (AB Frontier, Seoul, South Korea). A mouse antibody to E. coli DnaK was purchased (Enzo Lifescience, Farmingdale, NY) and used to detect V. vulnificus DnaK as a loading control (31). The V. vulnificus cultures grown to various A600 values were harvested and fractionated into cells and supernatants by centrifugation. The cells were lysed using cCompleteTM Lysis-M EDTA-free buffer (Roche, Mannheim, Germany) for 10 min, and residual cell debris was removed by centrifugation to obtain clear lysates. The supernatants were filtered through a PuradiscTM 25-mm syringe filter (pore size 0.2 µm; GE Healthcare) and concentrated using Amicon Ultra-15 (cut-off 10 kDa; Millipore, Temecula, CA), HlyU, CRP, and DnaK in the clear cell lysates (equivalent to 10 µg of total protein) or VvPlpA in the supernatant concentrates (equivalent to 2 µg of total protein) were determined by Western blot analyses, as described previously (60). Similarly, culture medium of INT-407 (ATCC® CCL-6) human epithelial cells, infected with the V. vulnificus strains at an MOI of 10 or 2 h, were 5-fold concentrated and resolved by SDS-PAGE, and then the actin and CypA were detected by Western blot analyses as described previously (61).

Proteins of interest were detected with the following antibodies and reagent. Rabbit anti-VvPlpA (1:1,000), rabbit anti-V. vulnificus HlyU (1:1,000), rabbit anti-V. vulnificus CRP (1:5,000), mouse anti-E. coli DnaK (1:10,000; Enzo Lifescience), rabbit anti-CypA (1:1,000; Cell Signaling Technology, Beverly, MA), rabbit anti-actin (1:10,000; Cell Signaling Technology), HRP-conjugated goat anti-rabbit IgG (1:10,000, Sigma), and HRP-conjugated rabbit anti-mouse IgG (1:10,000, Sigma) antibodies and ECL SelectTM Western blotting detection reagent (GE Healthcare).

PLA2 activity assay

PLA2 activity was measured using the EnzChek® phospholipase A2 assay kit (Invitrogen) that consists of a fluorogenic PC substrate (red/green BODIPY PC-A2) specific to PLA2 (21). Briefly, the substrate/liposome mix was prepared by mixing 25 µl of 1 mM red/green BODIPY PC-A2 substrate in dimethyl sulfoxide, 25 µl of 10 mM 1,2-dioleoyl-sn-glycero-3-phospho- and 25 µl of 1,2-dioleoyl-sn-glycero-3-phospho-(1’-rac-glycerol) (sodium salt) in 5 ml of PLA2 assay buffer (Invitrogen). Various amounts of rPlpA were added to 50 µl of the substrate/liposome mix and incubated at room temperature for 0.5 h. When necessary, the culture supernatants of the V. vulnificus strains grown to an A600 of 0.9 were filtered and concentrated as described above and then added to the reaction mixture instead of rPlpA (equivalent to 2 µg of total protein). The cleavage of the sn-2 bond of the red/green BODIPY PC-A2 by the PLA2 results in an increase of fluorescence emission, which was measured by using a microplate reader with an excitation at 480 nm and emission at 515 nm (Tecan Infinite M200 reader, Männedorf, Switzerland). Data were normalized by subtracting the fluorescence emissions from appropriate negative control samples (mixed with rPlpA storage buffer or blank medium concentrate). The activity of the rPlpA was determined using the standard curve developed based on the fluorescence emission by the various units of honey bee venom PLA2.

RNA purification and transcript analysis

Total RNAs from the V. vulnificus strains grown to various A600 values were isolated using an RNeasy® minikit (Qiagen). For real-time qPCR, the concentrations of total RNAs from the strains were measured by using a NanoEasy Plus spectrophotometer (GE Healthcare). cDNA was synthesized from 1 µg of the total RNA by using the iScript™ cDNA synthesis kit (Bio-Rad), and real-time PCR amplification of the cDNA was performed by using the Chromo 4 real-time PCR detection system (Bio-Rad) with pairs of specific primers (Table 2), as described previously (62). Relative expression levels of the plpA mRNA were calculated by using the 16S rRNA expression level as the internal reference for normalization (50).

If required, the V. vulnificus strains were exposed to blood of uninfected mice (n = 3), MEM, or INT-407 cells for various incubation times. The mixture of V. vulnificus and the mouse blood (or V. vulnificus and the host cells) was centrifuged at 250 x g for 10 min to precipitate eukaryotic cells and debris in the mouse blood (or the host cells), and then the V. vulnificus cells were harvested from the supernatant and used to isolate total RNAs, as described previously (29).

For primer extension analysis, a 23-base primer PLPA06-R (Table 2) complementary to the coding region of plpA was end-labeled with [γ-32P]ATP and added to the RNA. The primer was then extended with SuperScript II RNase H- reverse transcriptase (Invitrogen). The cDNA products were purified and
resolved on a sequencing gel alongside sequencing ladders generated from pKK1505 with the same primer. The plasmid pKK1505 was constructed by cloning the 461-bp plpA upstream region extending from -345 to +116, amplified by PCR using a pair of primers PLPA06-F and -R (Table 2), into pGEM-T Easy (Promega, Madison, WI). The primer extension product was visualized using a phosphor image analyzer (BAS1500, Fuji Photo Film Co., Ltd., Tokyo, Japan).

**Mouse infection experiments**

Three different experiments were conducted using female ICR mice (7-week-old specific-pathogen free; Seoul National University). For this purpose, the *V. vulnificus* strains grown to an A600 of 0.5 were harvested and suspended in PBS to 10^6 or 10^8 cfu/100 μl for intragastric or intraperitoneal infection, respectively. Mouse lethality of the *V. vulnificus* strains was compared as described previously (n = 15 per group) (11). The mice were intraperitoneally injected with 30 μg of iron-dextran for each gram of body weight, immediately after which they were administered with 100 μl of the inoculum intragastrically. Survival of the mice was recorded for 24 h.

To determine the number of *V. vulnificus* strains in the blood of infected mice and to conduct hematological analyses, the mice, without an iron-dextran pretreatment, were intraperitoneally infected with 100 μl of the inoculum (n = 11 for each wild type and plpA mutant and n = 5 for PBS control). The mice were sacrificed at 4 h postinfection to obtain blood samples. Equal amounts of diluted blood samples of wild type- and plpA mutant–infected mice (n = 6) were spread on LBS agar containing polymyxin B (100 units/ml) to specifically count the *V. vulnificus* cells. The recovered bacterial cells were enumerated as cfu/100 μl of blood. The remaining blood samples were used for hematological analyses, as described previously (63). Briefly, MPXI was analyzed by using a hematological autoanalyzer (AVIDA 2120, Bayer Diagnostics, Giessen, Germany). The serum levels for ALB, AST, and ALT were measured by lyzer (AVIDA 2120, Bayer Diagnostics, Giessen, Germany). All manipulations of mice were approved by the Animal Care and Use Committee at Seoul National University.

**Cytotoxicity and cell morphology change**

Two different assays were performed using INT-407 cells. To determine cytotoxicity, the monolayers of INT-407 cells were prepared and infected with the *V. vulnificus* strains in a 96-well tissue culture plate (Nunc, Roskilde, Denmark), and LDH activities in the supernatant were measured as described previously (29). Morphological changes were also examined by staining the INT-407 cells, which were seeded onto 6-well culture dishes (Nunc) and infected with the *V. vulnificus* strains at an MOI of 10 for 1.5 h. Briefly, INT-407 cell membranes and nuclei were stained with Texas Red®-X–conjugated WGA (final 5 μg/ml; Thermo Fisher Scientific) and with Hoechst® 33342 (final 5 μg/ml; Thermo Fisher Scientific), respectively, for 10 min and then photographed using a fluorescence microscope (FLoid® cell imaging station, Thermo Fisher Scientific).

**Characterization of plpA in V. vulnificus**

**Construction of a set of plpA-luxCDABE transcriptional fusions**

The primer PLPAR005 (Table 2) carrying a SpeI restriction site was used in conjunction with one of the primers carrying an SacI restriction site, PLPAR001, PLPAR002, PLPAR003, or PLPAR004, to amplify the DNA of plpA extending up to -227, -157, -77, and +22 bp, respectively. The amplified DNA fragments were inserted into the SpeI-SacI–digested pBBR-lux carrying promoterless luxCDABE genes (64) to create four plpA-lux reporter constructs: pKK1514, pKK1515, pKK1516, and pKK1517. The constructs were then transferred into the *V. vulnificus* strains by conjugation. The cellular luminescences of the cultures grown to an A600 of 0.9 were measured using a microplate reader (Tecan Infinite M200 reader) and expressed in arbitrary RLUs as described previously (48).

**EMSA and DNase I protection assay**

The 461-bp plpA upstream region, extending from -345 to +116, was amplified by PCR using unlabeled PLPA06-F and [γ-32P]ATP-labeled PLPA06-R and as primers (Table 2). The binding of HlyU to the labeled DNA and electrophoretic analysis of the HlyU–DNA complexes have already been described (13, 56). The protein–DNA binding reactions with CRP were performed in the same manner as those with HlyU, except that the 1× CRP-binding buffer was used (49).

The same labeled 461-bp DNA was used for DNase I protection assays. The binding of HlyU or CRP to the labeled DNA and DNase I digestion of the protein–DNA complexes followed the procedures described previously (56). The digested DNA products were precipitated with ethanol and then resolved on a sequencing gel beside the sequencing ladders generated as described above. The gels were visualized using a phosphor image analyzer (BAS1500).

**Data analyses**

Averages and S.D. values were calculated from at least three independent experiments. Mouse mortality was evaluated using the Log Rank Test program (http://bioinf.wehi.edu.au/software/russell/logrank/). All other data were analyzed by Student’s t tests using the SAS program (SAS Institute Inc.). Significance of differences between experimental groups was accepted at a p value of <0.05.

**Transcriptome data accession number**

All raw transcriptome data were deposited in ArrayExpress (http://www.ebi.ac.uk/arrayexpress/) (67) under accession number E-MTAB-5629.

**Author contributions**—K. K. J., M. H. K., B. S. K., and S. H. C. designed the research; K. K. J., Z.-W. L., B. K., and B. S. K. performed the research; K. K. J., M. H. K., B. S. K., Y. H. J., H. J. H., and S. H. C. analyzed the data; and K. K. J., M. H. K., B. S. K., Y. H. J., H. J. H., and S. H. C. wrote the paper. All authors reviewed the results and approved the final version of the manuscript.

**Acknowledgments**—We thank all members of the Choi laboratories for valuable discussions and technical support.
Characterization of plpA in *V. vulnificus*

**References**

1. Oliver, J. D. (2015) The biology of *Vibrio vulnificus*. *Microbiol. Spectr.* 10.1128/microbiolspec.VE-0001-2014
2. Phillips, K. E., and Satchell, K. J. (2017) *Vibrio vulnificus*: from oyster colonist to human pathogen. *PLoS Pathog.* 13, e1006053
3. Jones, M. K., and Oliver, J. D. (2009) *Vibrio vulnificus*: disease and pathogenesis. *Infect. Immun.* 77, 1723–1733
4. Falkow, S. (1988) Molecular Koch’s postulates applied to microbial pathogenicity. *Rev. Infect. Dis.* 2, S274–S276
5. Jeong, H. G., and Satchell, K. J. (2012) Additive function of *Vibrio vulnificus* MARTXVv, and VvhA cytolysins promotes rapid growth and epithelial tissue necrosis during intestinal infection. *PLoS Pathog.* 8, e1002581
6. Petersen, T. N., Brunak, S., von Heijne, G., and Nielsen, H. (2011) SignalP 4.0: discriminating signal peptides from transmembrane regions. *J. Mol. Biol.* 367, 1381–1392
7. Schmiel, D. H., and Miller, V. L. (1999) Bacterial phospholipases and pathogenesis. *Microbes Infect.* 1, 1103–1112
8. Akoh, C. C., Lee, G. C., Liaw, Y. C., Huang, T. H., and Shaw, J. F. (2004) Phosphatidyldcholine-specific phospholipase and hemolysin of GDSL family of serine esterase/lipase.
9. Leibovici, L., Samra, Z., Konigsberger, H., Drucker, M., Ashkenazi, S., and Pitlik, S. D. (1995) Long-term survival following bacteremia and fungemia. JAMA 274, 807–812
10. Yonezawa, K., Horie, O., Yoshiba, A., Matsuki, S., Tenjin, T., Tsukamura, Y., Yoneda, M., Shibata, K., Koike, Y., Nomura, T., Yokoyama, M., Urahama, N., and Ito, M. (2010) Association between the neutrophil myeloperoxidase index and subsets of bacterial infections. *Int. J. Lab. Hematol.* 32, 598–605
11. Xie, D. L., Zheng, M. M., Zheng, Y., Gao, H., Zhang, J., Zhang, T., Guo, J. C., Yang, X. F., Zhong, X. P., and Lou, Y. L. (2017) *Vibrio vulnificus* induces mTOR activation and inflammatory responses in macrophages. *PLoS One* 12, e0181454
12. Akoh, C. C., Lee, G. C., Liaw, Y. C., Huang, T. H., and Shaw, J. F. (2004) Characterization of PlpA, a phospholipase A homolog from *Rickettsia typhi*. *J. Bacteriol.* 192, 3294–3303
13. Li, L., Mou, X., and Nelson, D. R. (2011) HlyU is a positive regulator of virulence gene expression. *J. Bacteriol.* 193, 1406–1415
14. Schmiel, D. H., and Miller, V. L. (1999) Bacterial phospholipases and pathogenesis. *Microbes Infect.* 1, 1103–1112
15. Petersen, T. N., Brunak, S., von Heijne, G., and Nielsen, H. (2011) SignalP 4.0: discriminating signal peptides from transmembrane regions. *J. Mol. Biol.* 367, 1381–1392
16. Schmiel, D. H., and Miller, V. L. (1999) Bacterial phospholipases and pathogenesis. *Microbes Infect.* 1, 1103–1112
17. Petersen, T. N., Brunak, S., von Heijne, G., and Nielsen, H. (2011) SignalP 4.0: discriminating signal peptides from transmembrane regions. *Nat. Methods* 8, 785–786
18. Petersen, T. N., Brunak, S., von Heijne, G., and Nielsen, H. (2011) SignalP 4.0: discriminating signal peptides from transmembrane regions. *Nat. Methods* 8, 785–786
19. Schmiel, D. H., and Miller, V. L. (1999) Bacterial phospholipases and pathogenesis. *Microbes Infect.* 1, 1103–1112
20. Petersen, T. N., Brunak, S., von Heijne, G., and Nielsen, H. (2011) SignalP 4.0: discriminating signal peptides from transmembrane regions. *Nat. Methods* 8, 785–786
21. Schmiel, D. H., and Miller, V. L. (1999) Bacterial phospholipases and pathogenesis. *Microbes Infect.* 1, 1103–1112
hemolysin in vivo and its pathogenic significance. Biochem. Biophys. Res. Commun. 324, 86–91.

41. Gavin, H. E., Beisser, N. T., and Satchell, K. J. (2017) The effector domain region of Vibrio vulnificus MARTX toxin confers biphasic epithelial barrier disruption and is essential for systemic spread from the intestine. PLoS Pathog. 13, e1006119.

42. Zong, W. X., and Thompson, C. B. (2006) Necrotic death as a cell fate. Genes Dev. 20, 1–15.

43. Hering, N. A., Richter, J. F., Krug, S. M., Günzel, D., Fromm, A., Bohn, E., Rosenthal, R., Bücke, R., Fromm, M., Troeger, H., and Schulzke, J. D. (2011) Yersinia enterocolitica induces epithelial barrier dysfunction through regional tight junction changes in colonic HT-29/B6 cell monolayers. Lab. Invest. 91, 310–324.

44. Kirk, J. S., Schaarschuch, K., Dalimov, Z., Lasorsa, E., Ku, S., Ramakrishnan, S., Hu, Q., Azabdaftari, G., Wang, J., Pili, R., and Ellis, L. (2015) Top2a regulates the disruption of tight junctions in colonic HT-29/B6 cell monolayers. J. Biol. Chem. 287, 47292–47299.

45. Green, J., Rolfe, M. D., and Smith, L. J. (2014) Transcriptional regulation of Vibrio vulnificus cytolytic hemolysin of Vibrio vulnificus hupA. Mol. Microbiol. 6, e60324–15.

46. Horseman, M. A., and Surani, S. (2011) A comprehensive review of Vibrio vulnificus: an important cause of severe sepsis and skin and soft-tissue infection. Int. J. Infect. Dis. 15, e157–e166.

47. Green, J., Rolfe, M. D., and Smith, L. J. (2014) Transcriptional regulation of bacterial virulence gene expression by molecular oxygen and nitric oxide. Virulence 5, 794–809.

48. Fang, F. C., Frawley, E. R., Tapscott, T., and Vázquez-Torres, A. (2016) Bacterial stress responses during host infection. Cell Host Microbe 20, 133–143.

49. Jeong, H. S., Lee, M. H., Lee, K. H., Park, S. J., and Choi, S. H. (2003) SmcR and cyclic AMP receptor protein coactivate Vibrio vulnificus vvpE encoding elastase through the RpoS-dependent promoter in a synergistic manner. J. Biol. Chem. 278, 45077–45081.

50. Choi, H. K., Park, N. Y., Kim, D. I., Chung, H. J., Ryu, S., and Choi, S. H. (2002) Promoter analysis and regulatory characteristics of vvhBA encoding cytolytic hemolysin of Vibrio vulnificus. J. Biol. Chem. 277, 47292–47299.

51. Oh, M. H., Lee, S. M., Lee, D. H., and Choi, S. H. (2009) Regulation of the Vibrio vulnificus hupA gene by temperature alteration and cyclic AMP receptor protein and evaluation of its role in virulence. Infect. Immun. 77, 1208–1215.

52. Kirk, J. S., Schaarschuck, K., Dalimov, Z., Lasorsa, E., Hu, Q., Ramakrishnan, S., Hu, Q., Azabdaftari, G., Wang, J., Pili, R., and Ellis, L. (2015) Top2a identifies and provides epigenetic rationale for novel combination therapeutic strategies for aggressive prostate cancer. Oncotarget 6, 3136–3146.

53. Mortazavi, A., Williams, B. A., McCue, K., Schaeffer, L., and Wold, B. (2008) Mapping and quantifying mammalian transcriptomes by RNA-seq. Nat. Methods 5, 621–628.

54. Kim, S., Bang, Y. J., Kim, D., Lim, J. G., Oh, M. H., and Choi, S. H. (2014) Distinct characteristics of OxyR2, a new OxyR-type regulator, ensuring expression of peroxiredoxin 2 detoxifying low levels of hydrogen peroxide in Vibrio vulnificus. Mol. Microbiol. 93, 992–1009.

55. Milton, D. L., O’Toole, R., Horstedt, P., and Wolf-Watz, H. (1996) Flagellin A is essential for the virulence of Vibrio anguillarum. J. Bacteriol. 178, 1310–1319.

56. Simon, R., Priester, U., and Pühler, A. (1983) A broad host range mobilization system for in vivo genetic engineering: transposon mutagenesis in Gram negative bacteria. Nat. Biotechnol. 1, 784–791.

57. Kim, B. S., Hwang, J., Kim, M. H., and Choi, S. H. (2011) Cooperative regulation of the Vibrio vulnificus nan gene cluster by NanR protein, cAMP receptor protein, and N-acetylmannosamine 6-phosphate. J. Biol. Chem. 286, 40889–40899.

58. Keen, N. T., Tamaki, S., Kobayashi, D., and Trollinger, D. (1988) Improved broad-host-range plasmids for DNA cloning in Gram-negative bacteria. Gene 70, 191–197.

59. Goo, S. Y., Lee, H. J., Kim, W. H., Kim, K. S., Lee, H. J., Park, D. K., Lee, H. J., Kim, S. M., Kim, K. S., Lee, H. J., and Park, S. J. (2006) Identification of OmpU of Vibrio vulnificus as a fibronectin-binding protein and its role in bacterial pathogenesis. Infect. Immun. 74, 5586–5594.

60. Sheffield, P., Garrard, S., and Derewenda, Z. (1999) Overcoming expression and purification problems of RhoGDI using a family of “parallel” expression vectors. Protein Expr. Purif. 15, 34–39.

61. Liu, J. G., Bang, Y. J., and Choi, S. H. (2014) Characterization of the Vibrio vulnificus 1-Cys peroxiredoxin Prx3 and regulation of its expression by the Fe-S cluster regulator IscR in response to oxidative stress and iron starvation. J. Biol. Chem. 289, 36263–36274.

62. Tian, X., Zhao, C., Zhu, H., She, W., Zhang, J., Liu, J., Li, Z., Zheng, S., Wen, Y. M., and Xie, Y. (2010) Hepatitis B virus (HBV) surface antigen interacts with and promotes Cyclophilin A secretion: possible link to pathogenesis of HBV infection. J. Virol. 84, 3373–3381.

63. Kim, S. M., Lee, D. H., and Choi, S. H. (2012) Evidence that the Vibrio vulnificus flagellar regulator FlhF is regulated by a quorum sensing master regulator SmcR. Microbiology 158, 2017–2025.

64. Lee, S. J., Jung, Y. H., Ryu, J. M., Jang, K. K., Choi, S. H., and Han, H. J. (2016) VvpE mediates the intestinal colonization of Vibrio vulnificus by the disruption of tight junctions. Int. J. Med. Microbiol. 306, 10–19.

65. Lenz, D. H., Mok, K. C., Lilley, B. N., Kulkarni, R. V., Wingreen, N. S., and Bassler, B. L. (2004) The small RNA chaperone Hfq and multiple small RNAs control quorum sensing in Vibrio harveyi and Vibrio cholerae. Cell 118, 69–82.

66. Wright, A. C., Simpson, L. M., Oliver, J. D., and Morris, J. G. (1990) Phenotypic evaluation of acapsular transposon mutants of Vibrio vulnificus. Infect. Immun. 58, 1769–1773.

67. Li, W., Cowley, A., Uludag, M., Gur, T., McWilliam, H., Squizzato, S., Park, Y. M., Buso, N., and Lopez, R. (2015) The EMBL-EBI bioinformatics web and programmatic tools framework. Nucleic Acids Res. 43, W580–W584.

68. Kolesnikov, N., Hastings, E., Keays, M., Melnichuk, O., Tang, Y. A., Williams, E., Dylag, M., Kurbatova, N., Brandizi, M., Burdett, T., Megy, K., Pilicheva, E., Rustici, G., Tikhonov, A., Parkinson, H., et al. (2015) ArrayExpress update-simplifying data submissions. Nucleic Acids Res. 43, D1113–D1116.